Compumedics Limited · ASX:CMP
Compumedics — Investor Presentation (October 2019)
22 slides from Compumedics's investor presentation, October 2019
Slide 1: Corporate Presentation
Corporate presentation September 2016 Cover sheet to be added – Simone Corporate Presentation October 2019 David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain Research - Ultrasonic B
Slide 2: Who is Compumedics?
Who is Compumedics? A leading global, innovative developer and manufacturer of medical devices for: Monitoring neurological Ultrasonic monitoring of Diagnosing disorders including long- Highly sophisticated blood flow through the sleep disorders term epilepsy monitoring brain research brain (Transcr
Slide 3: FY2019 – Performance Review
FY2019 – Performance Review ▪ Revenue $41.5m, EBITDA $5.9m, NPAT $4.0m FY19 FY18 Variance Comment Revenue growth across key international markets Revenue $41.5m $37.0m 12% for the core business, including China, DWL and US. Further partial booking of first MEG sale. Profitability grows as a result o
Slide 4: FY2019 – Performance Review
FY2019 – Performance Review ▪ Core: Asia business, and China in particular, strong with 26% lift in revenues over pcp. ▪ Core: DWL business 17% lift in revenues and US business 16%, FY19 compared to FY18. ▪ Core: Profitability grows as a result of the overall growth in revenues, including the furthe
Slide 5: Revenue Bridge Chart – FY18 to FY19
Revenue Bridge Chart – FY18 to FY19 45 40 35 30 25 20 15 10 5 0 Revenue FY18 USA Aust Asia Europe Revenue FY19 Fall Rise 5
Slide 6: EBITDA Bridge Chart – FY18 to FY19
EBITDA Bridge Chart – FY18 to FY19 9 8 7 6 5 4 3 2 1 0 EBITDA FY18 Revenue Margin Expenses Other Revenue FX EBITDA FY19 Fall Rise 6
Slide 7: Revenue Composition at $41.5m
Revenue Composition at $41.5m 30 June 2019 By geographic region By product/market Consumables 8% Customer Europe, Care 9% 22% Brain - USA, 33% Blood Flow Sleep - Monitoring Clinical 18% Diagnostics 26% Brain - Sleep - Research Nexus360 Asia, 34% Aust, 11% 18% 2% Brain - Clinical Monitoring 19% Softw
Slide 8: Growth Platform – Core and Step-Out
Growth Platform – Core and Step-Out Sales – schematic only FY19A FY20F FY21F FY22F FY23F Core - Base Core - Sleep/Neuro (Mid Market) Neuro - MEG Sleep - eHealth (Nexus360 & Somfit) • Step-out - NEURO – BRAIN IMAGING – First phase installation at Barrow Neurological Institute in Phoenix, AZ, USA has
Slide 9: Core Business – Premium Focus
Core Business – Premium Focus Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Research Global market – 250m 1,300m 20m 15m USD pa Compumedics market share 6% <1% 30% 35% (approximate) Aust – 1 Aust – 1 Aust – 1 Aust – 1 Compumedics USA – 2 USA – 3 USA –
Slide 10: Core Business – Growing revenues and earnings
Core Business – Growing revenues and earnings 45,000 7,000 40,000 6,000 35,000 5,000 30,000 25,000 4,000 20,000 3,000 15,000 2,000 10,000 5,000 1,000 - - 2013 2014 2015 2016 2017 2018 2019 Revenues EBITDA 1.2000 1.0000 0.8000 0.6000 0.4000 0.2000 0.0000 2013 2014 2015 2016 2017 2018 2019 AUD/USD Exc
Slide 11: Core Business – Consistent Net Cash Position
Core Business – Consistent Net Cash Position $m FY13 FY14 FY15 FY16 FY17 FY18 FY19 Cash 1.3 1.1 2.2 3.1 4.1 3.9 4.6 Trade receivables 8.1 8.6 9.8 11.9 13.1 18.3 16.0 Inventories 5.5 6.1 5.7 6.5 7.4 7.6 7.8 Capitalised R&D 3.5 2.9 2.7 2.4 2.4 4.0 6.8 Tax asset 0.0 0.0 0.0 0.5 0.8 0.1 0.0 PP&E 0.7 0.7
Slide 12: Core Business – Adding Mid-Tier Range
Core Business – Adding Mid-Tier Range Average Product Used for Bought by selling price Sleep and neurology, high end and Hospitals, doctors USD11,500 to Grael family price sensitive models and service providers USD17,500 Hospitals, doctors Somte PSG Sleep USD10,000 and service providers Hospitals, d
Slide 13: Next Generation Growth – Core and Step-out
Next Generation Growth – Core and Step-out Neuro Sleep Neuro Brain Blood Diagnostics – Diagnostics Diagnostics - Imaging Flow Diagnostics Clinic Cloud based sleep Long term epilepsy Leverage existing TCD Leverage CURRY Next generation diagnostic platforms for market penetration into technology and p
Slide 14: Core Business - Growth Drivers
Core Business - Growth Drivers Compumedics/Neuroscan innovative brain analysis software (CURRY 9 close to release) and high performance amplifiers are unrivalled world class technology. New ambulatory range to release in 2020. We have about 23,000 systems installed worldwide. Strong reputation and b
Slide 15: USA – CMP is number 3 Supplier
USA – CMP is number 3 Supplier USA Clinical Sales Force Expansion - Indicative More sales representatives = more revenue for both sleep and neurology Past USD3.5m FY2019 USD4.0m FY2020 USD7.0m FY2021 USD11.0m 15
Slide 16: China - We are the number 1 Premier Supplier
China - We are the number 1 Premier Supplier Compumedics Clients in China Sleep Neuroscience Neuroscan 28 2 Xin Jiang 5 Helongjiang Inner Mongolia 2 Jilin Beijing 88 2 Liaoning Ningxia 23 Qinhuangdao China Sales (invoiced) – USD’s QingHai 3 HeBei 10 3 Tianjin Dalian 2 3 16 12 Gansu 14 HeNan Welfang
Slide 17: Step out 1 - Brain Imaging: 1st sale secured
Step out 1 - Brain Imaging: 1st sale secured Opportunity Market & Competition Plan Outcome CMP’s CURRY brain analysis The MEG market is currently estimated H2 FY19 – first phase of CMP has sold and software is already the gold at about 20 systems a year at an MEG installation partially installed 1 s
Slide 18: Step out 2 - eHealth – Cloud Sleep Diagnostics
Step out 2 - eHealth – Cloud Sleep Diagnostics Nexus 360 Operational systems have been Compumedics is Key partners (professional developed for the cloud based continuing to seek being pursued cloud sleep capture, transfer appropriate third include web, diagnostics) sold and translation of medical gr
Slide 19: Directors & Executive Team Key Management
Directors & Executive Team Key Management David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 32 yrs Mr Tucson Dunn Mr. David Lawson Non Executive Director Chief Financial Officer CMP Tenure 12 months & Company Secretary CMP Tenure 20 yrs Mr. Warwick Freeman Kerry Hubick, Ph.D. Mr. Christoph
Slide 20: Investor Summary
Investor Summary Core business profitable with on-going growth opportunities in key global markets International sales force Compumedics remains expansion, neurology and sleep committed to continuing to market opportunity and earnings deliver superior returns to improvement initiatives to continue s
Slide 21: Disclaimer
Disclaimer This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estim
Slide 22: compumedics.com.au
compumedics.com.au 22